Literature DB >> 30143231

Metastatic squamous cell carcinoma of known and unknown primary origin treated with axillary or inguinal lymphadenectomy.

Michael M Wach1, Elke van Beek2, Reed Ayabe1, Samantha Ruff1, Zachary Brown1, Debra A Goldman2, Constantinos P Zambirinis2, Sepideh Gholami2, Melissa Pulitzer2, Jonathan Hernandez3, Daniel Coit4.   

Abstract

BACKGROUND: Metastatic squamous cell carcinoma (SCC) to the axillary or inguinal lymph nodes from an unknown primary source is rarely encountered. We sought to evaluate a cohort of patients with metastatic SCC managed by lymphadenectomy to determine their survival and to determine which clinicopathologic factors were associated with outcome.
METHODS: All patients undergoing axillary or inguinal lymphadenectomy for SCC at our institution were identified retrospectively. Patients were stratified by unknown primary (UP) vs known skin primary (KP) tumors. Pertinent data on patient, tumor, and treatment variables was collected.
RESULTS: We identified 51 patients who met inclusion criteria. Of those, 20 patients (39%) had UP metastatic SCC and 31 patients (61%) had KP. The 5-year overall survival for UP was 65%, as compared to 49% for KP (p = 0.16). Cumulative incidence of recurrence was 46%. Cox regression failed to demonstrate a significant association between KP vs UP, HPV status, chemotherapy, or radiation with survival.
CONCLUSIONS: Nearly two-thirds of patients undergoing axillary or inguinal lymphadenectomy for metastatic SCC of unknown primary were alive five years following the procedure.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2018        PMID: 30143231     DOI: 10.1016/j.amjsurg.2018.06.006

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  1 in total

1.  Cancer of Unknown Primary Presenting as Bone-Predominant or Lymph Node-Only Disease: A Clinicopathologic Portrait.

Authors:  Ryan W Huey; Brandon G Smaglo; Jeannelyn S Estrella; Aurelio Matamoros; Michael J Overman; Gauri R Varadhachary; Kanwal P S Raghav
Journal:  Oncologist       Date:  2021-02-15
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.